EMT is a reversible biological program in which epithelial cells lose characteristics associated with organized tissue structure and acquire mesenchymal properties. During this transition, cancer cells typically reduce cell-cell adhesion, change shape, become more mobile, and gain greater capacity to invade surrounding tissues. EMT has long been associated with metastasis and treatment resistance, but the molecular factors that connect EMT to improved survival after DNA damage remain incompletely understood.

To search for such factors, the research team used an epigenomic strategy centered on broad regions of trimethylated histone H3 lysine 4, known as H3K4me3. This chromatin modification is commonly associated with active gene promoters. When H3K4me3 domains extend across larger genomic regions, they can mark genes that are particularly important for maintaining cellular identity or controlling major changes in cell behavior. The investigators compared these domains before and after transforming growth factor beta, or TGF-β, induced EMT in lung adenocarcinoma cells.

C/EBPγ emerged from this analysis as a candidate regulator whose chromatin-associated activity increased during EMT. Functional experiments supported that prediction. When researchers introduced C/EBPγ into lung adenocarcinoma cells, the cells developed an elongated, mesenchymal-like appearance, reduced their production of E-cadherin, and increased expression of mesenchymal markers. E-cadherin is a key protein involved in epithelial cell adhesion, and its loss is a widely used molecular indicator of EMT. Cells containing additional C/EBPγ also showed enhanced migratory behavior, whereas depletion of the endogenous protein weakened EMT-associated gene expression and impaired the transition.

The mechanism was notable because C/EBPγ did not require its conventional DNA-binding domain to induce EMT. Instead, the protein depended on its leucine zipper domain, a structural region that enables protein-protein interactions. This result suggests that C/EBPγ functions less as a conventional DNA-binding transcriptional switch and more as a molecular partner that modifies the activity of other regulatory proteins. The distinction is important because it identifies protein-interaction interfaces, rather than only DNA-recognition sites, as potential targets for future therapies.

Proteomic analyses revealed that C/EBPγ interacts with C/EBPβ, another member of the CCAAT/enhancer-binding protein family. In the lung adenocarcinoma models used in the study, C/EBPβ acted as a suppressor of EMT, while C/EBPγ promoted the transition by antagonizing C/EBPβ through leucine zipper-dependent interactions. In this model, the balance between related C/EBP proteins appears to influence whether cancer cells retain epithelial features or adopt a more invasive state. This antagonistic relationship provides a possible explanation for how C/EBPγ can drive EMT without directly binding DNA through its own DNA-binding domain.

The researchers also identified an independent function involving DNA repair. C/EBPγ associated with XRCC5 and XRCC6, two core components of the non-homologous end joining pathway. NHEJ repairs DNA double-strand breaks by bringing broken DNA ends together and rejoining them, often without requiring a long matching sequence between the ends. Although the pathway can introduce small sequence changes, it is essential for rapidly repairing the potentially lethal breaks produced by chemotherapy and other forms of genotoxic stress.

In laboratory experiments, C/EBPγ enhanced NHEJ activity and accelerated the recruitment of XRCC6 to sites of DNA damage. Cells expressing the factor accumulated fewer DNA damage markers after exposure to etoposide, a drug that induces DNA breaks by interfering with topoisomerase II. The findings indicate that C/EBPγ does not merely help cancer cells adopt a more adaptable and mobile phenotype; it also improves their ability to restore damaged chromosomes after treatment.

The consequences were observed in both cell-based assays and mouse xenograft models. Lung adenocarcinoma cells expressing C/EBPγ survived DNA-damaging chemotherapy more efficiently than control cells, and tumors containing the factor were less sensitive to etoposide treatment. When the leucine zipper domain was disrupted, the protective effect was lost, underscoring the importance of C/EBPγ’s interactions with other proteins. The study therefore presents C/EBPγ as a molecular hub that coordinates two features of aggressive disease: EMT-driven cellular plasticity and enhanced repair of therapy-induced DNA damage. Although further work will be needed to determine whether the mechanism operates broadly across patient tumors, disrupting C/EBPγ or its interaction surfaces could eventually provide a way to resensitize lung adenocarcinoma to DNA-damaging treatments.

Subject of Research: C/EBPγ-mediated epithelial-mesenchymal transition, DNA double-strand break repair, and therapy resistance in lung adenocarcinoma

Article Title: C/EBPγ induces epithelial-mesenchymal transition and facilitates DNA double-strand break repair in lung adenocarcinoma cells

News Publication Date: 2 June 2026

Web References: https://doi.org/10.1038/s41420-026-03181-0

References: Cell Death Discovery, DOI: 10.1038/s41420-026-03181-0

Image Credits: Terashima M. et al., Cell Death Discovery (2026), Figure 7F

Keywords: C/EBPγ, lung adenocarcinoma, epithelial-mesenchymal transition, EMT, DNA double-strand breaks, non-homologous end joining, XRCC5, XRCC6, therapy resistance, cancer biology, DNA repair, C/EBPβ

Uveal melanoma originates in the uvea, a pigmented tissue layer situated between the retina and the sclera, or the eye’s white outer layer. Its clinical course is often aggressive; nearly half of patients develop metastases, predominantly in the liver, where therapeutic options are distressingly limited. The inability of current mouse models to recapitulate this disease’s natural history has impeded translational progress. By genetically engineering mice to harbor the same sequential mutations characteristic of human uveal melanoma—starting with the activation of the GNAQ oncogene, followed by deletion of the tumor suppressor gene BAP1, and culminating in MYC oncogene amplification—researchers have created a system that faithfully replicates tumor initiation, progression, and phenotypic diversity.

This model represents an intricate approach to cancer modeling, activating a GNAQ mutation that alone induces benign ocular lesions akin to nevi in patients. The subsequent loss of BAP1 triggers malignant transformation, and amplification of MYC correlates with heightened tumor aggression and histopathological features resembling those seen in lethal human cases. This stepwise genetic manipulation underscores the multi-hit hypothesis of oncogenesis, elucidating how cumulative alterations drive malignancy’s advancement while preserving physiological relevance by maintaining an intact immune system.

Intriguingly, the study elucidates the phenotypic plasticity of uveal melanoma cells. Cancer cells within the tumors do not constitute a homogenous population; instead, subpopulations exhibit distinct states. Some retain characteristics similar to normal melanocytes, while others adopt aggressive phenotypes associated with poor clinical outcomes. This cellular heterogeneity likely contributes to the tumor’s notorious resilience and capacity for metastasis. The model facilitates in-depth dissection of how tumors shift cellular states dynamically, possibly in response to environmental pressures or therapeutic interventions, mirroring phenomena previously described in cutaneous melanoma.

A particularly compelling aspect of the research involves the immune microenvironment. Both in this mouse model and human tumors, immune cells infiltrate the tumor but remain dysfunctional, effectively stymied by the cancer’s immunosuppressive tactics. Such immune evasion tactics help explain why conventional immunotherapy, so successful in other melanoma types, remains largely ineffective for uveal melanoma. By reproducing this immune landscape, the model opens avenues for developing tailored immunotherapies, designed to overcome the unique barriers found in ocular tumors.

Furthermore, researchers identified molecular biomarkers linked to aggressive tumor phenotypes within the model. These biomarkers offer potential for refining prognostication and personalizing treatment protocols. Existing clinical tools inadequately predict metastatic risk, and these newly discovered biomarkers, grounded in a replicable in vivo system, promise to enhance risk stratification and catalyze biomarker-driven clinical trials. This could herald a new era of precision medicine in eye cancer treatment.

The model’s ability to mimic tumor spread to the liver—albeit initially without extensive metastatic outgrowth—makes it a valuable tool for probing the mechanisms underlying organ tropism. Understanding why uveal melanoma cells preferentially colonize the liver, while sparing other organs, remains a significant scientific puzzle. Researchers hypothesize that disseminated cells undergo state transitions that enable migration and colonization, subsequently reverting to a proliferative state to establish secondary tumors. This model provides an experimental venue to test these hypotheses systematically, potentially revealing interventions to disrupt metastatic colonization or dormancy escape.

Beyond the insights into tumor biology, this immune-competent and genetically engineered mouse model equips the scientific community with a tool to evaluate novel therapeutic regimens in a physiologically relevant context. It supports studies that investigate immune checkpoint inhibitors, adoptive cell therapies, and combination treatments tailored to the unique genetic and immunological features of uveal melanoma. By enabling preclinical screening of immunotherapies before human trials, this model may accelerate the advent of effective treatments for a cancer that currently offers a grim prognosis.

The stepwise approach taken to model uveal melanoma genetics aligns with best practices established in other cancer research fields. Incorporating multiple patient-relevant mutations and maintaining an intact functional immune system enhances the model’s clinical relevance. It underscores a paradigm where preclinical studies leverage genetically engineered mouse models that recapitulate the heterogeneity and complexity of human cancers to optimize translational potential. This approach is likely to inspire similar strategies across diverse malignancies requiring nuanced modeling.

A crucial advancement made by the scientists is their ability to restrict the effects of oncogenic mutations in spatially and temporally controlled manners, ensuring that early benign lesions form similarly to human nevi before malignant progression. This refinement contrasts with earlier models where immediate tumor formation skewed interpretations and failed to reproduce disease kinetics. This nuanced control allows researchers to dissect initiation, progression, dormancy, and metastasis phases with unprecedented granularity.

The identification of phenotypic plasticity within uveal melanoma cells invites further exploration of epigenetic mechanisms and signaling pathways that regulate state transitions. Understanding these processes could reveal vulnerabilities exploitable for therapeutic intervention, such as targeting state-switching machinery to prevent metastasis or therapy resistance. The model offers a robust platform for interrogating these dynamic cancer cell behaviors, advancing efforts to counteract tumor adaptability.

In conclusion, the development of this multi-step, immune-competent genetically engineered mouse model represents a landmark accomplishment in ocular melanoma research. Its capacity to recapitulate tumor genetics, cellular heterogeneity, immune interactions, and metastatic behavior provides a transformative tool to unravel the baffling biology of uveal melanoma. By enabling rigorous preclinical testing of targeted and immunotherapeutic approaches, this model holds promise for accelerating the discovery of life-saving treatments for patients afflicted by this devastating eye cancer.

Subject of Research: Animals

Article Title: A Multi-Step Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma

News Publication Date: 10-Feb-2026

Web References:

• Moffitt Cancer Center: http://moffitt.org/
• Uveal Melanoma Information: https://www.moffitt.org/cancers/melanoma/diagnosis/types/ocular-melanoma/
• Research Article in Cancer Research: https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-25-2684/774239/A-Multi-Step-Immune-Competent-Genetically

References:
Karreth, F., et al. (2026). A Multi-Step Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma. Cancer Research. DOI: 10.1158/0008-5472.CAN-25-2684

Keywords: Eye cancers, uveal melanoma, mouse model, immune microenvironment, cancer genetics, GNAQ mutation, BAP1 deletion, MYC amplification, phenotypic plasticity, metastasis, immunotherapy, tumor biomarkers

Breast tissue is dynamic, undergoing profound transformations throughout a woman’s life. From embryonic stages through puberty and hormonal changes associated with pregnancy and lactation, breast cells transition between mesenchymal and epithelial states. The mesenchymal phase marks an early developmental stage characterized by round, highly motile, and rapidly dividing cells. In contrast, the epithelial phase represents a mature, cuboidal cell morphology with limited motility and slower proliferation. Under normal physiological conditions, cells shuttle between these states through tightly regulated mechanisms that ensure tissue homeostasis.

However, the hijacking of this natural plasticity is central to breast cancer initiation and progression. Malignancy often begins when epithelial breast cells regress, recapitulating the mesenchymal phenotype that confers enhanced migratory capacity and uncontrolled proliferation—hallmarks of cancer. Intriguingly, this same cellular plasticity facilitates the opposite transition during metastasis, allowing disseminated cancer cells to revert to a dormant epithelial-like state characterized by cell cycle arrest and metabolic quiescence. This dormant state is thought to shield cancer cells from therapies and immune surveillance, enabling them to persist quietly in distant organs for prolonged intervals.

One of the pivotal discoveries from Yarden’s laboratory focuses on the role of OVOL proteins, transcription factors instrumental in regulating the epithelial-mesenchymal axis during normal breast development. Leveraging a sophisticated three-dimensional tumor microenvironment model, combined with genetic engineering techniques, the researchers induced overexpression of OVOL1 and OVOL2 proteins in highly aggressive triple-negative breast cancer (TNBC) cells—cancers notorious for their poor prognosis and limited treatment options. Remarkably, heightened OVOL expression arrested the cellular lifecycle of these TNBC cells, enforcing dormancy and dramatically suppressing tumor growth both in vitro and in vivo in xenografted female mice.

Despite the intuitive appeal of halting tumor growth, OVOL1’s involvement in dormancy revealed a dark paradox. The team found that breast tissues of cancer patients frequently harbor elevated OVOL1 levels, suggesting a dual role for this protein. In the short term, OVOL1 suppresses proliferation, acting as a brake on malignancy. Over the long term, however, elevated OVOL1 facilitates cancer cell survival by enabling the dormancy program, allowing cells to evade detection and persist in the body. When environmental or hormonal changes trigger a decline in OVOL1 expression, dormant cells abruptly resume proliferation, often displaying heightened aggressiveness.

Further interrogation of the molecular controls governing OVOL expression uncovered critical regulatory influences of growth factors and steroid hormones. Specifically, the study revealed that certain growth factors promote OVOL1 synthesis, reinforcing dormancy, whereas estrogen—through its receptor pathway—suppresses OVOL1 expression. This interaction elucidates clinical observations correlating low estrogen receptor levels and elevated OVOL1 with worse prognoses, particularly in TNBC patients. These findings implicate hormonal milieu shifts, such as those occurring during menopause or weight gain, in modulating dormancy dynamics and recurrence risk.

The tantalizing implications extend to observed epidemiological patterns. Postmenopausal fat tissue becomes a significant source of estrogen production, potentially lowering OVOL1 levels systemically and thus awakening dormant tumor cells. This novel link may transform clinical management strategies for survivors by spotlighting weight management and hormone modulation as preventive measures against relapse. Prof. Yarden emphasizes the need for future animal and human studies to validate these hypotheses and develop targeted interventions that could block dormancy onset or tumor resurgence.

Central to the study’s groundbreaking contribution is its elucidation of the biochemical cascade triggered by OVOL1-induced dormancy. The research team identified an unexpected accumulation of reactive oxygen species—primarily free radicals—within dormant cancer cells. These unstable molecules induce extensive oxidative damage, disrupting DNA integrity and stalling the cell cycle, thereby enforcing the dormant state. Significantly, prior to this report, the involvement of oxidative stress in cancer cell dormancy had not been described, marking a paradigm shift in the understanding of tumor biology.

Continuing their investigation in collaboration with Prof. Emeritus Yosef Shiloh at Tel Aviv University, the researchers uncovered profound genomic consequences of sustained oxidative stress during dormancy. The delicate balance of nuclear proteins responsible for DNA repair becomes disrupted by oxidation, compromising the function of three critical repair factors. As a result, dormant cells accumulate a substantial mutational burden during their quiescent phase, an insight that challenges the classical notion of dormancy as mere cellular suspension and depicts it as an active phase of genetic evolution.

This accumulation of mutations appears to underlie the phenomenon of aggressive relapse after dormancy. When dormant cancer cells re-enter the cell cycle, their altered genome equips them with enhanced survival capabilities and resistance to conventional therapies. These findings may partly explain why recurrent breast tumors often defy standard treatment regimens and harbor more malignant traits compared to their primary counterparts.

Prof. Yarden calls attention to the translational potential of these discoveries, noting that dormancy is not unique to breast cancer but is a feature shared by many malignancies such as prostate and melanoma. By dissecting the molecular and biochemical underpinnings of dormancy, this research opens new avenues for intercepting cancer progression by either preventing dormancy induction or forestalling the reawakening of latent tumor cells. This strategical pivot could revolutionize cancer therapeutics by addressing one of the primary sources of treatment failure and mortality.

In conclusion, the intricate dance between epithelial and mesenchymal states in breast cancer cells, orchestrated by OVOL proteins and modulated by hormonal and oxidative forces, emerges as a critical determinant of cancer dormancy and relapse. The recognition that dormant cells accumulate DNA damage and evolve during their quiescent phase recasts dormancy as a dynamic, high-stakes biological state rather than a simple pause. These revelations not only deepen our grasp of tumor biology but also herald a future where managing dormancy could translate into prolonged remission and enhanced survival for breast cancer patients worldwide.

Subject of Research: Mechanisms of breast cancer cell dormancy and relapse with a focus on OVOL proteins, oxidative stress, and hormonal regulation.

Article Title: Re-epithelialization of cancer cells increases autophagy and DNA damage: Implications for breast cancer dormancy and relapse

News Publication Date: 22-Apr-2025

Web References:
Science Signaling DOI 10.1126/scisignal.ado3473

Keywords: Breast cancer, tumor tissue, discovery research, cellular proteins, mutant proteins, cellular processes, cancer research, breast cancer cells